NO986218L - FremgangsmÕte til Õ bestemme nµrvµr av hjerneprotein S-100 - Google Patents

FremgangsmÕte til Õ bestemme nµrvµr av hjerneprotein S-100

Info

Publication number
NO986218L
NO986218L NO986218A NO986218A NO986218L NO 986218 L NO986218 L NO 986218L NO 986218 A NO986218 A NO 986218A NO 986218 A NO986218 A NO 986218A NO 986218 L NO986218 L NO 986218L
Authority
NO
Norway
Prior art keywords
procedure
determining
brain protein
brain
protein
Prior art date
Application number
NO986218A
Other languages
English (en)
Norwegian (no)
Other versions
NO986218D0 (no
Inventor
Jan Brundell
Lena Nyberg
Original Assignee
Sangtec Medical Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sangtec Medical Ab filed Critical Sangtec Medical Ab
Publication of NO986218D0 publication Critical patent/NO986218D0/no
Publication of NO986218L publication Critical patent/NO986218L/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5751—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the skin, e.g. melanoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO986218A 1996-07-05 1998-12-30 FremgangsmÕte til Õ bestemme nµrvµr av hjerneprotein S-100 NO986218L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9602677A SE9602677D0 (sv) 1996-07-05 1996-07-05 Methods for determining brain antigens
PCT/SE1997/001164 WO1998001471A1 (en) 1996-07-05 1997-06-27 Methods for determining the presence of brain protein s-100

Publications (2)

Publication Number Publication Date
NO986218D0 NO986218D0 (no) 1998-12-30
NO986218L true NO986218L (no) 1998-12-30

Family

ID=20403304

Family Applications (1)

Application Number Title Priority Date Filing Date
NO986218A NO986218L (no) 1996-07-05 1998-12-30 FremgangsmÕte til Õ bestemme nµrvµr av hjerneprotein S-100

Country Status (13)

Country Link
EP (1) EP0931094B1 (de)
JP (1) JP2000515854A (de)
AT (1) ATE301671T1 (de)
AU (1) AU715797B2 (de)
BR (1) BR9710175A (de)
CA (1) CA2259413A1 (de)
DE (1) DE69733957T2 (de)
ES (1) ES2247633T3 (de)
IL (1) IL127278A0 (de)
NO (1) NO986218L (de)
NZ (1) NZ333408A (de)
SE (1) SE9602677D0 (de)
WO (1) WO1998001471A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1107994B1 (de) * 1998-08-28 2006-04-26 Canag Diagnostics AB Monoklonale antikörper gegen s100
WO2000026668A2 (en) * 1998-11-05 2000-05-11 The Regents Of The University Of Michigan S100 proteins and autoantibodies as serum markers for cancer
CA2263063C (en) 1999-02-26 2004-08-10 Skye Pharmatech Incorporated Method for diagnosing and distinguishing stroke and diagnostic devices for use therein
US6780606B1 (en) 1999-02-26 2004-08-24 Synx Pharma, Inc. Method for diagnosing and distinguishing stroke and diagnostic devices for use therein
EP1216417A1 (de) * 1999-09-28 2002-06-26 Evotec OAI AG Quantitative analyse und typisierung subzellulärer partikel
AU2001265714A1 (en) * 2000-06-14 2001-12-24 Universite Libre De Bruxelles Marker for neurodegenerative diseases and its use for drug screening targeted against said diseases
ES2394972B2 (es) * 2011-06-17 2013-07-19 Universidade De Santiago De Compostela Péptido antigénico aislado derivado de la proteína s100-beta, procedimiento de identificación y su uso en la prevención, tratamiento, diagnóstico y/o seguimiento de la diabetes tipo i.
ES2394331B2 (es) * 2011-06-17 2013-07-15 Universidade De Santiago De Compostela Uso de un péptido antigénico aislado derivado de la proteína s100-beta no unido a una molécula mhc de clase ii en la prevención, tratamiento, diagnóstico y/o seguimiento de la diabetes tipo i
CN102331502B (zh) * 2011-08-31 2013-12-04 内蒙古科慧生物科技有限责任公司 人s100蛋白(s-100)定量测定试剂盒
WO2014194329A1 (en) * 2013-05-31 2014-12-04 Banyan Biomarkers, Inc. NEURAL SPECIFIC S100β FOR BIOMARKER ASSAYS AND DEVICES FOR DETECTION OF A NEUROLOGICAL CONDITION
CN111487409A (zh) * 2019-01-28 2020-08-04 艾维可生物科技有限公司 一种s100b蛋白的化学发光法检测试剂盒及其使用方法

Also Published As

Publication number Publication date
NO986218D0 (no) 1998-12-30
AU3563397A (en) 1998-02-02
DE69733957T2 (de) 2006-04-13
CA2259413A1 (en) 1998-01-15
IL127278A0 (en) 1999-09-22
AU715797B2 (en) 2000-02-10
NZ333408A (en) 1999-05-28
EP0931094A1 (de) 1999-07-28
WO1998001471A1 (en) 1998-01-15
ES2247633T3 (es) 2006-03-01
BR9710175A (pt) 2000-01-11
ATE301671T1 (de) 2005-08-15
DE69733957D1 (de) 2005-09-15
SE9602677D0 (sv) 1996-07-05
JP2000515854A (ja) 2000-11-28
EP0931094B1 (de) 2005-08-10

Similar Documents

Publication Publication Date Title
FR12C0004I2 (fr) Anticorps contre l'antigene ctla-4 humain et utilisation
EP0751992A4 (de) Vaskularer endothelialer wachstumsfaktor 2
DK0536275T3 (da) Tumorvækstinhibitorer udledt fra væv, fremgangsmåde til deres fremstilling samt anvendelse heraf
CA2310888A1 (en) Monoclonal human natural antibodies
NO20010567D0 (no) Zonulin peptidantagonister og fremgangsmåter for anvendelse av disse
EP0909814A3 (de) Verwendung von Proteinkinasen zur Diagnose und Behandlung der Alzheimer'schen Krankheit
EA199800946A1 (ru) Концентрированный препарат антител
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
AU1130392A (en) Synthetic htlv-iii peptides, compositions and uses thereof
ATE250625T1 (de) IM WESENTLICHEN REINES ZONULIN ALS PHYSIOLOGISCHER MODULATOR VON ßTIGHT JUNCTIONSß BEI SÄUGERN
EP0959896A4 (de) Zusammensetzungen auf der grundlage des humanen thyrotropinrezeptors und ihre verwendung
NO986218L (no) FremgangsmÕte til Õ bestemme nµrvµr av hjerneprotein S-100
NO971341L (no) Promoter for reseptor tyrosinkinase TIE
DE69333076D1 (de) Test und behandlung von demyelinierenden krankheiten wie multiple sklerosis
DE69638024D1 (de) Melanoma antigene p15 und deren anwendung in diagnostischen und therapeutischen verfahren
AU9363398A (en) Hepatitis c receptor protein cd81
ATE265533T1 (de) Saeugetierchemokine
NO173336C (no) Fremgangsm}te til isolering av basalmembranproteiner fra human- eller animalvev og anvendelse av det oppn}dde protein
KR910006478A (ko) 인체 트립타제 유사 단백질
EP0780472A3 (de) Stress Proteine
WO1998041538A3 (en) Novel human cytokine/steroid receptor protein
WO2000017658A3 (en) Diagnosis of myocardial disease or stroke using factor ix activation peptide
ES2136534A1 (es) Uso de la cd-1 sacalina para la deteccion y seguimiento de la enfermedad celiaca.
ATE169332T1 (de) Monoklonaler antikörper gegen den extravillösen trophoblast
IT1286182B1 (it) Impiego della relaxina o relassina, come nuovo agente farmacologico antistaminico per bloccare il rilascio di istamina nei tessuti in

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application